PIPELINE
Immuno-oncology Platform
Cellemedy develops innovative treatment of cancer for better health for human world-wide
Human Ferritin – Iron-free 24mer of H- & L-chain
Human Ferritin

Iron-free 24mer of H- & L-chain
Human Protein Stable at High Temperature and at pH 4-10.
Excellent Human Body Suitability and Stability with Low Inflammatory Response and Immunogenicity.
(PNAS 2014, 111:13900 / Intern. Emerg. Med. 2006, 1:187 / ACS Nano2014, 7:4830 / Front.Chem. Sci. Eng. 2017, 11:633)
Development of Immune Checkpoint Inhibitors
and Cancer Vaccine based on Human Ferritin with Low Immunogenicity
Chemotherapy
Cancer Cure
Attacks Cells Indiscriminately
Target Cancer Therapy
Cancer Target Cure
Limited Cancer Cure Effect
Drug Resistance
Immunotherapy
(Vaccine, Immune Checkpoint Inhibitor)
Wide Range Cure Effect
Patient Specific
Cure Metastatic and Recurrent Cancer
Drug Resistance
Side Effect
Difficult to Cure Drug Resistance
High Cost and Long Development Time
Promotes Cancer-specific Immune Cells
Low Immunity Effect by Antigen
Adjuvant Toxicity

‘Innovative Strategy’ using
huHF Platform

Synergy of Immune Checkpoint Inhibitor and Cancer-cure Vaccine : Next Generation Immunotherapy.
-
Human Ferritin(huHF) Platform for of Immune Checkpoint Inhibitor and Cancer-cure Vaccine
-
Excellent Cancer-cure Effect by Synergy of Immune Checkpoint Inhibitor and Cancer-cure Vaccine
ㅣImmune Checkpoint Cure: Comparing to Existing Antibody Cure
· Excellent Cure Effect
· Low Immunogenicity
· Lower Drug Resistance
ㅣCancer-cure Vaccine
· Efficient T-cell Boosting Effect
· No Adjuvants Needed(No Side Effects)
-
Low Manufacturing Cost
Better Accessibility for Patients
Synergy – Vaccination + IC therapy
(melanoma (B16F10))

Combination therapy schedule

Days after tumor challenge
Cellemedy Pipeline

-
Cancer Immunotherapy
ㅣplatform - Human Ferritin Platform
· Bi-specific Immune Checkpoint Blocker
· Efficient Carrier for Antigen
ㅣSynergy of Immune Checkpoint Inhibitor and Cancer-cure Vaccine
ㅣSolution for Existing Immunotherapy
· Cooperation with Korea University